October 9, 2023 5:01pm

The rising geopolitical tension/risks in Israel caused by the Hamas invasion/massacres had cell and gene therapy sector consequences, potential energy markets surges with nominal markets for now impact so far … while bond market was closed

News: Alnylam Pharmaceuticals (ALNY -$8.60 or -4.86%) wanted to expand approval of its drug Onpattro, but the FDA rejected the heart drug application even after an outside advisory committee voted in favor of it.

Pre-open Indications: 3 Hits and 3 Miss

Subscription is coming, it is not conscription but, an offer to join our collective of like-minded investors!  Join me … in the NO spin zone.

The war winds are accelerating and the blowing dust-up cloud will spread; it will take many a day/week/month to understand what the impact will actually be?

Never leave an investor uninformed! 

The Dow closed UP +197.07 points or +0.59%, the S&P closed UP +27.16 points or +0.63% while the Nasdaq closed UP +52.90 points or +0.39%

 

What’s SAFE … “No one company is immune in the sector and this market of rolling downdrafts? Welcome to my world of defining the “grey’ in our universe!”

Investors are going to need to prepare for another reporting cycle to confirm whether or not a bottom is even close to happening.

 

Henry’omics:

We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes staged a comeback Monday as investors tried to shake off pressures driven by the deadly Israel-Hamas conflict.

The rising geopolitical tensions caused by the conflict could have ramifications for the energy market, with some experts forecasting a brief surge in crude prices but overall limited impact. The rising tension could also serve to stoke further volatility in market that has kept traders worried with persistent inflation and higher interest rates. <CNBC>

Economic Data Docket: None

 

Monday (10/9) … RegMed Investors’ (RMi) Opening Bell: “who’s flashing buy signals or not After murderous attack/massacre on Israel, war response weighs financial markets?” … https://www.regmedinvestors.com/articles/13154   

Pre-open Indications: 3 Hits <CRISPR Therapeutics (CRSP -$0.55), Intellia Therapeutics (NTLA -$0.01), Voyager Therapeutics (VYGR +$0.12)>  and 3 Miss <Beam Therapeutics (BEAM +$0.49), Alnylam Pharmaceuticals (ALNY -$8.60), Sage Therapeutics (SAGE -$0.10)>

RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened – differences …

  • Monday’s advance/decline line opened negative at 2 up/ 29 down and 4 flats, stayed negative with 7 up/ 26 down and 2 flats at the mid-day, ending with a negative close of 10 incliners, 23 decliners and 2 flats

 

Ebb and flow:

Q4:  October – 4 negative and 2 positive closes

·         Q3: September – 1 holiday, 8 positive and 12 negative closes

·         August – 9 positive and 14 negative closes

·          July - 1 holiday, 12 positive and 8 negative close

 

Key Metrics:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Monday, the IBB was down -0.36% and the XBI was down -0.79%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Monday was up +0.21 point or +1.20% at 17.66

 

Closing Down (10 of 23):

  • Alnylam Pharmaceuticals (ALNY -$8.60 after Friday’s -$1.79),
  • CRISPR Therapeutics (CRSP -$0.55 after Friday’s +$0.06),
  • uniQure NV (QURE -$0.34 after Friday’s +$0.23),
  • Verve Therapeutics (VERV -$0.29 after Friday’s +$0.36),
  • BioLife Solutions (BLFS -$0.23 after Friday’s +$0.28),
  • AxoGen (AXGN -$0.20 after Friday’s -$0.14),
  • bluebird bio (BLUE -$0.19 after Friday’s -$0.23),
  • Prime medicine (PRME -$0.17),
  • Caribou BioSciences (CRBU -$0.14 after Friday’s -$0.05),
  • Editas Medicine (EDIT -$0.14)

Flat (2):

  • Brainstorm Cell Therapeutics (BCLI)
  • Harvard Apparatus GN (HRGN $0.00 after Friday’s +$0.58)

Closing Up (10 of 10):

  • Blueprint Medicine (BPMC +$0.98 after Friday’s +$0.16),
  • Beam Therapeutics (BEAM +$0.49 after Friday’s -$0.83)
  • Ultragenyx Pharmaceuticals (RARE +$0.45),
  • Vericel VCEL +$0.27),
  • Regenxbio (RGNX +$0.18),
  • Voyager Therapeutics (VYGR +$0.12 after Friday’s +$0.21),
  • Generation Bio (GBIO +$0.06 after Friday’s -$0.12),
  • Ionis Pharmaceuticals (IONS +$0.05 after Friday’s -$0.46),
  • Graphite BIO (GRPH +$0.03 after Friday’s -$0.06),
  • Mesoblast (MESO +$0.02)

 

Q4/23 – October

  • Monday (10/9) closed negative with 10 incliners, 23 decliners and 2 flats

 

The BOTTOM LINE: Israeli Prime Minister Benjamin Netanyahu declare his country is at war after Hamas/Palestinian fighter/terrorists.

What is more to write or say as terrorism pervades/penetrates our world again and to express our horror!

As uncertainty looms in Monday's trading, markets appear more focused on what the Fed has to say than be rattled by Israel's declaration of war on Hamas.

  • Sentiment is definitely slipping as exits appear in the sixth (6th) session of the new month and Q.
  • The Nasdaq improved from the day's lows and trimmed 0.1% in afternoon stock market action.
  • Volume fell in the Nasdaq compared with Friday's trading at the same time of day in stock market action.

 

The cell and gene therapy sector equities share pricing on Monday and Friday declined after Thursday “ascension” post pooping the bed, Wednesday after rising on Tuesday following negative closes on last Monday.

 

A relevant quote, "Geopolitical risk doesn't tend to linger long in markets, but there are many second-order impacts that could come through in the weeks, months, and years ahead from this weekend's developments." <Deutsche Bank strategist Jim Reid>.

 

Focus should be on the upcoming quarterly earnings season!

The top three (3) performing in the session:

Monday: Vericel (VCEL), Beam Therapeutics (BEAM) and Ultragenyx Pharmaceuticals RARE)  

The worst three (3) in the session:

Monday: Alnylam Pharmaceuticals (ALNY), CRISPR Therapeutics (CRSP) and uniQure NV (QURE)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.